Dana-Farber partners with Merck

New Jersey-based drug maker Merck and Co. said today it has entered into an agreement with the Dana-Farber Cancer Institute of Boston to create a team approach to cancer drug development.

Merck said it will work with Dana-Farber's Center for Applied Cancer Science to identify promising drug targets and develop therapeutic candidates to reach those targets.

Lynda Chin, a medical doctor at Dana-Farber who will be the senior investigator in the collaboration, said in a statement, "By actively facilitating communication, this new agreement represents an important advance toward true team science between Dana-Farber and one of world's the leading pharmaceutical companies."
(By Chris Reidy, Globe staff)